Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated a positive growth trajectory in its revenue, with fourth-quarter 2025 revenue reaching $174.4 million, reflecting a 4% increase quarter-over-quarter and an 8% increase year-over-year, outperforming prior estimates due to robust domestic sales of Optune Gio. The company is poised for future growth as it has secured national reimbursement in Spain, anticipated to contribute significantly in 2026, and clinical trials like the TRIDENT trial may expand patient eligibility for Tumor Treating Fields (TTFields) technology. Continued positive dynamics in the U.S. market, coupled with enhanced access to glioblastoma treatments through a trained sales force and community centers, indicate a strong outlook for NovoCure’s operational performance.

Bears say

NovoCure Ltd. is facing a negative outlook primarily due to revised revenue forecasts stemming from lackluster performance in its commercial efforts, particularly related to its Optune product line. The company has lowered its 2026 revenue estimates for Glioblastoma (GBM) to $690 million from $702 million, and total revenue estimates have also decreased to $711.3 million compared to a previous estimate of $738.9 million. Furthermore, significant risks such as potential safety concerns, lower-than-expected clinical efficacy, and heightened competition could adversely affect the company's financial performance and market position.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.